Complete financial analysis of Inozyme Pharma, Inc. (INZY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Inozyme Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- The Valens Company Inc. (VLNS.TO) Income Statement Analysis – Financial Results
- Cyber Digital, Inc. (CYBD) Income Statement Analysis – Financial Results
- Tarsier Ltd. (TAER) Income Statement Analysis – Financial Results
- Libra Insurance Company Ltd (LBRA.TA) Income Statement Analysis – Financial Results
- JHS Svendgaard Laboratories Limited (JHS.NS) Income Statement Analysis – Financial Results
Inozyme Pharma, Inc. (INZY)
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.29M | 1.18M | 1.05M | 217.00K | 83.00K | 26.00K |
| Gross Profit | -1.29M | -1.18M | -1.05M | -217.00K | -83.00K | -26.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 54.85M | 47.85M | 37.72M | 46.49M | 16.22M | 8.10M |
| General & Administrative | 20.80M | 20.83M | 18.93M | 10.55M | 4.59M | 3.49M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.80M | 20.83M | 18.93M | 10.55M | 4.59M | 3.49M |
| Other Expenses | 0.00 | -319.00K | -189.00K | 247.00K | -24.00K | 4.35M |
| Operating Expenses | 75.65M | 68.68M | 56.65M | 57.04M | 20.81M | 11.59M |
| Cost & Expenses | 75.65M | 68.68M | 56.65M | 57.04M | 20.81M | 11.59M |
| Interest Income | 7.84M | 1.93M | 211.00K | 370.00K | 1.11M | 284.00K |
| Interest Expense | 3.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 833.00K | 1.18M | 1.05M | 217.00K | 83.00K | 26.00K |
| EBITDA | -74.81M | -65.88M | -55.97M | -56.82M | -20.72M | -11.57M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -75.65M | -68.68M | -56.65M | -57.04M | -20.81M | -11.59M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.48M | 1.61M | 22.00K | 617.00K | 1.08M | 4.63M |
| Income Before Tax | -71.17M | -67.06M | -56.62M | -56.42M | -19.72M | -6.96M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.61M | -211.00K | -587.00K | -1.11M | 4.63M |
| Net Income | -71.17M | -65.45M | -56.41M | -55.84M | -18.62M | -6.96M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.37 | -1.73 | -2.39 | -2.39 | -1.23 | -0.46 |
| EPS Diluted | -1.37 | -1.73 | -2.39 | -2.39 | -1.23 | -0.46 |
| Weighted Avg Shares Out | 51.84M | 37.76M | 23.56M | 23.38M | 15.16M | 15.14M |
| Weighted Avg Shares Out (Dil) | 51.84M | 37.76M | 23.56M | 23.38M | 15.16M | 15.14M |
Inozyme Pharma to Present at Cowen 42nd Annual Health Care Conference
BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer, will...
Inozyme Pharma (INZY) Stock: $23 Price Target From Needham
The shares of Inozyme Pharma Inc (NASDAQ: INZY) have received a $23 price target from Needham. These are the details.
Wall Street Analysts Believe Inozyme Pharma, Inc. (INZY) Could Rally 257%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 256.5% in Inozyme Pharma, Inc. (INZY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate...
Inozyme Pharma to Present at Upcoming Investor Conferences
BOSTON, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief...
Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program at the ASBMR 2021 Annual Meeting
- Natural History Study shows ectopic calcification and/or cardiovascular disease could serve as distinguishing characteristics of ENPP1 Deficiency in some children with rickets -
INZY Stock: Why It Increased Today
The stock price of Inozyme Pharma Inc (NASDAQ: INZY) increased by over 15% during intraday trading today. This is why it happened.
Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
BOSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief...
Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business Highlights
- Received Orphan Drug Designation from the European Medicines Agency for INZ-701 for the treatment of ABCC6 Deficiency –
Inozyme Pharma to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference
BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced Axel Bolte, MSc, MBA, the company's co-founder, president, and chief executive officer,...
Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency
INZ-701 was previously granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for ENPP1 Deficiency INZ-701 was previously granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for...
Source: https://incomestatements.info
Category: Stock Reports